Adenovirus-p53-mediated apoptosis has been extensively evaluated in animal xenografts derived from human epithelial tumors and recently began testing in phase I clinical trials, but has not been evaluated for lymphoid malignancies. Cell lines derived from anaplastic large cell lymphoma (ALCL) carrying the t(2;5) translocation are efficiently transduced by adenoviral vector expressing p53 and undergo apoptosis. To test the in vivo efficiency of adenovirusmediated-p53 expression and apoptosis induction, SUDHL-1 cells (derived from human ALCL) were injected subcutaneously into athymic nude mice. Cells from the xenograft had typical morphology of human ALCL by standard hematoxylin-eosin staining, CD5 + , CD45
Adenovirus-p53-mediated gene therapy has been evaluated in animal xenografts derived from human epithelial tumor cell lines. [1] [2] [3] [4] The promising results of in vivo induced apoptosis and tumor growth inhibition in animal models have set the ground for phase I human clinical trials. [5] [6] [7] Although the exogenous expression of p53 mediated by an adenoviral vector is a well established molecular therapeutic tool for solid tumors, it has been explored only recently in lymphoid malignancies. 8 We have shown efficient killing of cells derived from lymphoid malignancies induced by adenoviral vector expressing wild-type p53. 8 In a more recent study, we also evaluated the transfer and the expression of the wild-type p53 tumor suppressor gene by an adenoviral vector (AdWtp53) in SUDHL-1 cells derived from anaplastic large cell lymphoma (ALCL). 9 The exogenous expression of wild-type p53 after adenoviral vector gene transfer induced SUDHL-1 cells to undergo apoptosis. Apoptosis occurred after G 1 phase cell cycle arrest and resulted in the death of 85% of cells in vitro. 9 Although controls (uninfected and AdNull) showed endogenous expression of p53 only cells infected with AdWTp53 underwent apoptosis. 9 Even if we did not study the genotype of p53 expressed by SUDHL-1, this was consistent with a mutant p53. 9 In the current study we tested the effects of adenovirus-mediated-p53 expression and apoptosis induction in vivo. Athymic nude mice were injected subcutaneously with SUDHL-1 cells to establish tumors. Tumor growth regression or inhibition induced by in vivo exogenous p53 expression was evaluated.
Tumor growth of a human lymphoma cell line as xenograft in the subcutaneous tissue of nude mice was initially explored. ALCL xenograft has been reported using JB6 cells in SCID mice. 10 The tumor cells were injected subcutaneously after passage within the peritoneal cavity of the SCID mice. For our model using SUDHL-1 cells the direct injection of 1 × 10 7 cells in each posterior flank of the mouse induced tumor growth in 60% of athymic nude mice (Figure 1a and b) . Protocol for experiments with mice was reviewed and approved by institutional committee for animal care.
ALCL is an intermediate-grade non-Hodgkin's lymphoma with high propensity to invade the skin and grow as nodule or papule. The skin is one of the more frequent 
(c) Large cells highly undifferentiated with irregular nuclei are shown in section stained with hematoxyllin-eosin (400 ×). (d) Sections were stained with anti-CD30 and peroxidase as shown in (400 ×). Matched isotype was used as control (not shown). (e) The immunophenotype of the SUDHL-1 cells in tissue culture was compared with the immunophenotype of the cells derived from the xenograft. Cells were stained with a panel of T and B lymphocyte specific antigens and analyzed by flow cytometry (Coulter, Miami, FL, USA). (f) PCR analysis of the genomic DNA extracted with standard method from SUDHL-1, SUPM2 (also derived from human ALCL), mouse xenograft and Jurkat (acute lymphoblastic leukemia). SUDHL-1, SUPM2 and Jurkat were suspension cells kept in tissue culture with RPMI 1640 (Gibco BRL, Gaithersburg, MD, USA) at different concentrations of fetal bovine serum (FBS). The 5Ј primer NPMA1-CG GTT GTG AAC TAA AGG CCG ACA AAG ATT ATC and the 3Ј primer ALK1-C ACC TCC TTC AGG TCA CTG ATG GAG GAG GTC were used to amplify the NPM-ALK fusion of the t(2;5) and they were based on published sequence. 16 A 457 bp band was present in SUDHL1, in SUPM2 and in the cells derived from the tumor grown in the mouse. This was consistent with the same genotype t(2;5). Jurkat was the negative control.
sites of extra-lymphoid tissue colonization. 11, 12 Morphological similarity of the xenograft to the human ALCL tumor were evident on paraffin-embedded sections stained with hematoxylin-eosin. The cells were highly undifferentiated with irregular nuclei, larger than normal lymphocytes and typical appearance of this particular lymphoma (Figure 1c (Figure 1f) as the original phenotype previously described. 13 This was consistent with stability of the cell line over the years.
In order to assess p53-induced apoptosis and necrosis in vivo, six tumors from an initial set of mice were injected only once with 1 × 
Paraffin-embedded tumor sections were dehydrated in serial ethanol and xylene washings. After incubation with proteinase K, the sections were stained with TUNEL (terminal deoxynucleotidyl transferase) assay according to the manufacturer's instructions (Boehringher Mannheim, Indianapolis, IN, USA). Slides were observed for fluorescence using Niakon Diaphot 300 microscope (Nikon, Japan). TUNEL staining for AdWTp53 (a) and mock (b) are shown. Tumor sections were stained with hematoxylin-eosin and evaluated for necrosis. Nuclear pyknosis, karyorrhexis, karyolysis (arrowheads) and coagulation necrosis (arrows) are present in tumors infected AdWTp53 (c). Normal cellularity with intact nuclei is evident in tumors injected with PBS (d) and AdNull (not shown).
2b). Tumors were evaluated for necrosis to verify whether the initial event of apoptosis had induced cell death as previously shown in vitro. 9 The same tumors previously assessed for apoptosis were stained with hematoxylin-eosin and evaluated for pyknosis, karyorrhexis, karyolysis of the nuclei or coagulation necrosis in cases (Figure 2c ) and controls (Figure 2d) . Two hundred cells per 10 high power fields were counted on slides that were blinded to the pathologist. Difference of the means was statistically significant at P = 0.02 between AdWTp53-1 and mock and borderline between AdWTp53 and AdNull ( Figure 3) . Tumor areas injected with AdWTp53 showed areas of cell necrosis concentrated (but not exclusively localized) in proximity to the needle track. In contrast control tumors had minimal necrosis mainly localized at the periphery of the tumor (ischemic necrosis mainly due to tumor overgrowth).
After we demonstrated that in vivo apoptosis and necrosis was induced in tumors injected with AdWTp53, the next question was whether injection with AdWTp53 could inhibit ALCL-tumor growth. Established SUDHL-1 tumors on a separate set of mice were subsequently directly injected with 1 × 10 8 p.f.u. of either AdWTp53 (n = 8 tumors) or AdNull (n = 8 tumors) and PBS (n = 7 tumors). Each tumor was injected three times to maximize tumor transduction. Injections were administered every 48-78 h and a total of 23 tumors was then analyzed for volume variation over time (18 days).
A caliper directly on animals measured tumors during the period of observation (see legend of Figure 4 ). There was no statistically significant difference of the mean initial volume among tumors injected with PBS, AdNull and AdWTp53, respectively ( Table 1 ). The mean volume of tumors injected with AdWTp53 was significantly smaller than control tumors injected with AdNull or PBS (Table 1 and Figure 4) . The control tumors were increased in size over the time and none of them reached a size plateau (Figure 4) . These results clearly demonstrated that repeated injections of AdWTp53 induce tumor regression or growth arrest compared with controls.
Recent studies have evaluated the use of adenoviral vectors to transduce in vitro lymphoid cells using effector genes like p53, 8 herpes simplex thymidine kinase 8 and interleukin-2.
14 A more recent study showed efficiency of cell killing ex vivo in cells harvested from the bone marrow of patients with multiple myeloma. 15 The killing mechanism was mediated by adenovirus-expressed thymidine kinase and ganciclovir and used in the context of bone marrow purging. We have also shown in vitro that adenovirus-mediated p53 expression induced apoptosis in several lymphoid-derived cell lines. 8, 9 The current study presents an in vivo attempt at gene therapy using an adenoviral vector expressing p53 to treat tumors derived from a peculiar type of human lymphoma in nude mice. Initially we were able to show in vivo apoptosis and to confirm our previous results obtained in vitro. 9 Subsequently we demonstrated that serial injections of AdWTp53 caused tumor growth inhibition in tumors from a separate set of animals. Complete tumor regression was not routinely seen either reflecting the resistance of some tumor cells to p53 killing or a lack of required gene transfer efficiency, due to the increased distance from the needle track. This latter is related to the tumor size. Tumors which were initially smaller or an increased frequency of injections would have probably showed complete tumor regression. We did not evaluate the tumors from the second set of animals for apoptosis and necrosis as we did with those from the previous set ( Figure 2 ).
Although these results are not definitive they are
Gene Therapy encouraging for consideration of gene therapy to be used as a treatment of lymphoid malignancies.
